The Center for Molecular Medicine has added one more partnership to its growing list of leading-edge tests and treatments coming to West Michigan, and this latest venture supports three tests developed for treatment of metastatic cancer. The tests will help physicians customize care for individual cancer patients.
According to excerpts from the story:
The Center for Molecular Medicine (CMM) today announced an agreement with San Diego-based AviaraDx to support three new tests that help physicians personalize cancer treatment.
The AviaraDx tests can provide physicians greater understanding of the molecular biology underlying patients' tumors. These test results will help physicians make more informed decisions in managing their oncology patients.
Read the complete story here.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.